Phase 2 N=5 Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy
Retinal Disease
Primary: Change in Visual Acuity at Month 3 Compared to Baseline. — 0 ETDRS letters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 Eplerenone for the Treatment of Central Serous Chorioretinopathy
Central Serous Chorioretinopathy
Primary: Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement. — 139.3; 135.9; 51.8; 172.3 microns
Phase 2 N=12 The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
Central Serous Chorioretinopathy
Primary: Safety of Intravitreal Aflibercept Injection — 0; 0 adverse events
Phase 2 N=34 Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
Chronic Central Serous Chorioretinopathy
Primary: Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment — 16; 2 participants
Phase 2 N=15 Eplerenone for Central Serous Chorioretinopathy
Central Serous Chorioretinopathy
Primary: Complete Resolution of Subretinal Fluid — 0 participants
Phase 2 N=5 Topical Interferon Gamma-1b for Central Serous Chorioretinopathy
Retinal Disease · Macular Disease
Primary: Total Number of Severe Ocular Adverse Events Related to the Investigational Product — 0 Adverse Events
N/A N=24 Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy
Central Serous Chorioretinopathy
Primary: Multifocal Electroretinogram Amplitudes — 28.4; 32.2; 29.7; 36.1 microvolts
Phase 2 N=3 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy
Retinal Disease
Primary: Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at Two Years Compared to Baseline — 0 ETDRS letters
Phase 2 N=22 Sildenafil for Treatment of Choroidal Ischemia
Choroidal Ischemia · Vitelliform Macular Dystrophy · Age-related Macular Degeneration
Primary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR
N/A N=30 A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
Central Retinal Vein Occlusion
Primary: Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts — 12.5; 14; 13.5 letters read correctly
Phase 4 N=44 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Retinal Degenerations
Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants
Phase 4 N=333 Aflibercept in Polypoidal Choroidal Vasculopathy
Neovascular Macular Degeneration
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last…
Phase 3 N=357 Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Macular Edema · Central Retinal Vein Occlusion
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline — 12.3 Letters
Phase 1 N=6 Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema
Uveitic Cystoid Macular Edema
Primary: Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months. — 12.2 Change in ETDRS Letters — p=0.0015
Phase 2 N=16 Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
Central Retinal Vein Occlusion
Primary: Incidence and Severity of Ocular and Systemic Adverse Events — 1; 0; 0; 1 participants
Phase 4 N=322 Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
Age-related Macular Degeneration · Polypoidal Choroidal Vasculopathy
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 - Study Eye — 8.3; 5.1 Letters — p=<0.001
Phase 3 N=702 Treatment for CI-DME in Eyes With Very Good VA Study
Diabetic Macular Edema
Primary: Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline — 33; 36; 39 Eyes
Phase 2 N=129 Phase II Combination Steroid and Anti-VEGF for Persistent DME
Diabetic Macular Edema
Primary: Mean Change in Visual Acuity Letter Score — 2.7; 3.0 Letter Score
Phase 1 N=7 Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Choroidal Neovascularization
Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…
Phase 4 N=49 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative Age-related Macular Degeneration
Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer
Phase 2 N=22 Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion
Diabetic Macular Edema
Primary: Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters…
Phase 3 N=321 Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
Macular Degeneration · Choroidal Neovascularization
Primary: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 — 53.7; 54.6; 54.8; 59.0 Letters
Phase 4 N=162 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO
Central Retinal Vein Occlusion
Primary: The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to…
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
Phase 2 N=5 Sirolimus to Treat Diabetic Macular Edema
Diabetic Retinopathy
Primary: Change in Visual Acuity From Baseline to 6 Months — 7; 0 ETDRS letters
N/A N=12 Multimodal Analysis and Electroretinogram in VKH From Acute Onset - Part I
Uveomeningoencephalitic Syndrome · Inflammation · Choroid Disease
Primary: Median Values of ERG Scotopic Parameters at 12-month — 201; 210; 508; 92 microvolts — p=<0.001
Phase 3 N=682 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
Macular Edema, Cystoid · Retinal Vein Occlusion
Primary: The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit — 5…
Phase 2 N=46 Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Macular Edema · Retinal Vein Occlusion
Primary: Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm — 18; 7; 3; 12 Participants
N/A N=30 Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion
Central Retinal Vein Occlusion With Macular Edema
Primary: Visual Acuity — 0.32; 0.44 logMAR units
N/A N=6 Feasibility Study of a Chronic Retinal Stimulator in Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Number of Adverse Events From 2 Weeks Post-op Until the End of the Study — 34 total number of AEs